

## CURRICULUM VITAE: Ferran Torres, MD, PhD

Spanish; born April 11<sup>th</sup>, 1964

Main Address            Medical Statistics core facility<sup>1</sup>  
IDIBAPS<sup>2</sup> - Hospital Clinic Barcelona<sup>3</sup>  
183, Mallorca Street. Floor -1. Office #60. 08036 Barcelona  
Phone: +34 932 279 328 / Fax: +34 932 279 877  
[Ferran.Torres@idibaps.org](mailto:Ferran.Torres@idibaps.org)

Secondary Address        Biostatistics Unit<sup>4</sup>. Faculty of Medicine<sup>5</sup>.  
Universitat Autònoma de Barcelona (UAB)<sup>6</sup>  
08193 Bellaterra (Barcelona). Spain  
Phone: +34 93 581 23 46 / 19 03. Fax: +34 93 581 23 44  
[Ferran.Torres@uab.es](mailto:Ferran.Torres@uab.es)

Miscellanea                Short presentation at: <http://ferran.torres.name/about-me/>  
ResearchGate =>[https://www.researchgate.net/profile/Ferran\\_Torres](https://www.researchgate.net/profile/Ferran_Torres)  
ResearcherId: D-1296-2011 =><http://www.researcherid.com/rid/D-1296-2011>  
ORCID: 0000-0002-7355-7913 =><http://orcid.org/0000-0002-7355-7913>  
SCOPUS: 7102336718 =><http://www.scopus.com/authid/detail.url?authorId=7102336718>

### EDUCATION

1993-1998    PhD in Medicine. Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona.

Doctoral thesis: "Methodological and statistical issues in the design of sequential clinical trials".

Director: Prof. Victor Moreno (Unit of Biostatistics, Department of Public Health. School of Medicine Universitat Autònoma de Barcelona. Tutorship: Prof. Josep Torrent. Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona

Defended in March 1998: "Excel.lent Cum Laude."

1989-92    Medical Specialist in Clinical Pharmacology, Hospital Universitari Vall d'Hebron, Barcelona.

1982-88    Degree in Medicine and Surgery. Universitat Autònoma de Barcelona, Barcelona.

### PROFESSIONAL EXPERIENCE

#### • Current position

Since 2014                Chair of the "Methodology, Biostatistics and Data Management Program"<sup>7</sup>, in the SCReN network (Spanish Clinical Research Network)<sup>8</sup>, program funded by the national institute of health (*Instituto de Salud Carlos III -ISCIII*<sup>9</sup>)

Since 2013-                Permanent External Reviewer of the ECRIN<sup>10</sup> standard procedures

---

1 Medical Statistics core facility, <http://www.idibaps.org/core-facilities/11/medical-statistics>

2 IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer. [http://www.idibaps.org/en\\_index.html](http://www.idibaps.org/en_index.html)

3 Hospital Clínic Barcelona, <http://www.hospitalclinic.org/en>

4 Biostatistics Unit, <http://www.uab.es/servlet/Satellite/research/dept-pediatric-of-obstetrics-and-gynecology-and-preventive-medicine-1242716174878.html>

5 Faculty of Medicine, <http://www.uab.es/servlet/Satellite/faculty-of-medicine-1241503829669.html>

6 UAB, <http://www.uab.cat/web/universitat-autonoma-de-barcelona-1345467954774.html>

7 Methodology, Biostatistics and Data Management Program at SCReN. <https://www.scren.es/en/program-mbdmp.php>

8 SCReN, Spanish Clinical Research Network, <https://www.scren.es/en/>

9 Instituto de Salud Carlos III, ISCIII, <http://www.eng.isciii.es/ISCIII/es/contenidos/fd-internacional/presentacion.shtml>

10 European Clinical Research Infrastructure Network (ECRIN). <http://www.ecrin.org>

- Since Juny-2009 Member of the Biostatistics Group (BSWP)<sup>11</sup> at the EMA (European Medicines Agency)<sup>12</sup>.
- Since Juny-2008 Member of the SAWP<sup>13</sup> (Scientific Advice Working Group) of the EMA (European Medicines Agency).
- Since 2007 Head of the Biostatistics and Data Management Core Facility. Hospital Clínic. Barcelona.
- Methodological and statistical support to other Hospital Medical Services for the design, conduction, analyses and reporting of clinical trials and research projects.
  - Member of the ECRIN network; member of the Data Management Working Group.
  - Researcher at several independent research projects.
- Since 1999 Statistical consultant for the Clinical Evaluation section, (*Agencia Española del Medicamento y Productos Sanitarios -AEMPS*<sup>14</sup>-):
- Elaboration and discussion of methodological guidelines: rapporteur “CPMP/EWP/1776/99 Points to Consider on Missing Data”, and member of the working group discussion “Points to Consider on the Calculation and Reporting of the Prevalence of a Condition for Orphan Designation” and “CHMP/EWP/83561/05. Guideline on Clinical Trials in Small Populations”.
  - Support to AEM and Efficacy Working Party expert for the writing of methodological guidelines, Committee for Proprietary Medicinal Products, European Agency for the Evaluation of Medicinal Products (EMA).
  - Support to the Spanish assessors in the review of dossiers of register and scientific advice since 2000.
  - Education: Training on methodological and statistical issues to the AEMPS since 2002. Teacher at the Assessor Training meeting at EMA, 2002. Workshop on Methodological Aspects of Clinical Trials for Efficacy Evaluation in Small Populations: Sequential designs EMA 2002.
- Since 1994 Associate Professor, Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona (UAB).
- Teaching of statistics and methodology to undergraduate and post-graduate students.
- Since 1993 Senior Consultant at the Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona (UAB).
- Responsible for the methodological design and analysis of clinical trials (since 1993, more than 70 bioequivalence and phase I clinical trials, and more than 40 phase III-IV clinical trials.)

• Former experience

- 2004-2007 Senior Consultant. Clinical Pharmacology Department. Hospital Clínic Barcelona.
- 2002-2007 Member of the Ethic’s Committee at Institut Univeritari Dexeus (Barcelona)
- 1996-2002 Biometrics responsible, Clinical Pharmacology Department, Hospital de Sant Pau, Barcelona
- 1989-1992 Resident physician at of the Clinical Pharmacology Service. Ciutat Sanitària Universitària de la Vall d'Hebron (Barcelona).
- 1992 Stage at the General Directorate of Drugs and Health Products. Spanish Ministry of Health.
- 1992-1993 Granted at the Unit of Biostatistics. School of Medicine. Universitat Autònoma de Barcelona.

---

11 BSWP at EMA,

[http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people\\_listing\\_000065.jsp&mid=WC0b01ac0580232514](http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000065.jsp&mid=WC0b01ac0580232514)

12 EMA, <http://www.ema.europa.eu/ema/>

13 SAWP, [http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people\\_listing\\_000022.jsp](http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000022.jsp)

14 AEMPS, <https://www.aemps.gob.es/en/home.htm>

• Other

- Societies**
- Registered physician (Col·legi Oficial Metges de Barcelona) since 1988, No. 25820.
- Member of the Spanish Society of Clinical Pharmacology since 1990; Member of the Executive Committee since Oct 2002- current.
- Member of European Association of Clinical Pharmacology and Therapeutics.
- Member of XXI Congreso de la Sociedad Española de Farmacología Clínica (SEFC) 2008 Organizing Committee.
- Member of "Drug Information Association" (DIA) since 1993 up to date.
- Member of Biometría Clínica para la Investigación Farmacéutica Association since 1994.
- Languages**
- Spanish and Catalan: native languages.
- English: fluent spoken and written.

**Publications**

More than 200 published papers in indexed scientific journals with a cumulated IF of >1000. Listing includes references from 2008 onwards.

**2017**

Hazelbag CM, Peters SA, Blankestijn PJ, Bots ML, Canaud B, Davenport A, Grooteman MP, Kircelli F, Locatelli F, Maduell F, Morena M, Nubé MJ, Ok E, **Torres F**, Hoes AW, Groenwold RH; HDF Pooling Project investigators. The importance of considering competing treatment affecting prognosis in the evaluation of therapy in trials: the example of renal transplantation in hemodialysis trials. *Nephrol Dial Transplant*. 2017 Feb 27. doi: 10.1093/ndt/gfw458. [Epub ahead of print]. Impact\_Factor: 4,09

Lencioni R, Montal R, **Torres F**, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. *J Hepatol*. 2017 Jan 25. pii: S0168-8278(17)30016-8. doi: 10.1016/j.jhep.2017.01.012. [Epub ahead of print]. Impact\_Factor: 10,59

Silva-Junior G, Turon F, Baiges A, Cerda E, García-Criado Á, Blasi A, **Torres F**, Hernandez-Gea V, Bosch J, Garcia-Pagan JC. Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Porto-systemic Shunts in Patients With Portal Hypertension. *Gastroenterology*. 2017 Jan 24. pii: S0016-5085(17)30051-3. doi: 10.1053/j.gastro.2017.01.011. [Epub ahead of print]. Impact\_Factor: 18,187

**2016**

Abraldes JG; Villanueva C; Aracil C; Turnes J; Hernandez-Guerra M; Genesca J; Rodriguez M; Castellote J; Garcia-Pagan JC; **Torres F**; Calleja JL; Albillos A; Bosch J. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. *Gastroenterology*. 2016 May;150(5):1160-1170.e3. doi: 10.1053/j.gastro.2016.01.004. Epub 2016 Jan 14. Impact\_Factor: 18,187

Achhra A C; Mocroft A; Reiss P; Sabin C; Ryom L; de Wit S; Smith CJ; D'Arminio Monforte A; Phillips A; Weber R; Lundgren J; Law MG; **D:A:D Study Group**. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. *HIV Med*. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28. Impact\_Factor: 3,341

Boettiger DC; Sabin CA; Grulich A; Ryom L; Bonnet F; Reiss P; D'Arminio Monforte A; Kirk O; Phillips A; Bower M; Fatkenheuer G; Lundgren JD; Law M; **Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group**. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. *AIDS*. 2016 Jun 19;30(10):1629-37. doi: 10.1097/QAD.0000000000001053. Impact\_Factor: 4,407

Davenport A; Peters SA; Bots ML; Canaud B; Grooteman MP; Ascí G; Locatelli F; Maduell F; Morena M; Nube MJ; Ok E; **Torres F**; Woodward M; Blankestijn PJ. Higher convection volume exchange with online hemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size. *Kidney Int*. 2016 Jan;89(1):193-9. doi: 10.1038/ki.2015.264. Epub 2016 Jan 4. Impact\_Factor: 7,683

Escorsell A; **Torres F**; Catalina M; Mas A; Rios J; Guevara M. Short-term Survival in Acutely Decompensated Cirrhotic Patients. *Liver International*. 5 - 194, 2016. Impact\_Factor: 4,47

Friis-Moller N; Ryom L; Smith C; Weber R; Reiss P; Dabis F; De Wit S; D'Arminio Monforte A; Kirk O; Fontas E; Sabin C; Phillips A; Lundgren J; Law M; **D:A:D study group**. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. *Eur J Prev Cardiol*. 2016 Jan;23(2):214-23. doi: 10.1177/2047487315579291. Epub 2015 Apr 16. Impact\_Factor: 3,361

Gambato M; Crespo G; **Torres F**; Llovet L; Carrion J; Londono M; Lens S; Marino Z; Bartres C; Miquel R; Navasa M; Forns X. Simple prediction of long-term clinical outcomes in patients with mild hepatitis c recurrence after liver transplantation. *Transpl Int*. 2016 Jun;29(6):698-706. doi: 10.1111/tri.12730. Impact\_Factor: 2,835

Guanabens N; Filella X; Monegal A; Gomez-Vaquero C; Bonet M; Buquet D; Casado E; Cerda D; Erra A; Martinez S; Montala N; Pitarch C; Kanterewicz E; Sala M; Suris X; **Torres F**. Reference intervals for bone turnover markers in Spanish premenopausal women. *Clin Chem Lab Med*. 2016 Feb 1;54(2):293-303. doi: 10.1515/cclm-2015-0162. Impact\_Factor: 3,017

Hatleberg CI; Ryom L; El-Sadr W; Smith C; Weber R; Reiss P; Fontas E; Dabis F; Law M; D'Arminio Monforte A; De Wit S; Mocroft A; Phillips A; Lundgren JD; Sabin C; **D:A:D Study Group**. Improvements over time in short-term mortality following myocardial infarction in the D: A: D Study. *AIDS*. 2016 Mar 4. [Epub ahead of print]. Impact\_Factor: 4,407

Hochberg MC; Martel-Pelletier J; Monfort J; Möller I; Castillo JR; Arden N; Berenbaum F; Blanco FJ; Conaghan PG; Doménech G; Henrotin Y; Pap T; Richette P; Sawitzke A; du Souich P; Pelletier JP; **MOVES Investigation Group**. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. *Ann Rheum Dis*. 2016 Jan;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792. Epub 2015 Jan 14. Impact\_Factor: 12,384

Lens S; **Torres F**; Puigvehi M; Mariño Z; Londoño MC; Martínez SM; García-Juárez I; García-Criado Á; Gilibert R; Bru C; Solà R; Sanchez-Tapias JM;

- Carrión JA; Fornis X. Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. *Aliment Pharmacol Ther.* 2016 Feb;43(3):364-74. doi: 10.1111/apt.13472. Epub 2015 Nov 18. Impact\_Factor:6,32
- Nubé MJ, Peters SA, Blankestijn PJ, Canaud B, Davenport A, Grooteman MP, Asci G, Locatelli F, Maduell F, Morena M, Ok E, **Torres F**, Bots ML; HDF Pooling Project investigators. Mortality reduction by post-dilution online-haemodiafiltration: a cause-specific analysis. *Nephrol Dial Transplant.* 2016 Dec 26. pii: gfw381. doi: 10.1093/ndt/gfw381. [Epub ahead of print]
- Maduell F; Moreso F; Mora-Macia J; Pons M; Ramos R; Carreras J; Soler J; **Torres F**. ESHOL study reanalysis: All-cause mortality considered by competing risks and time-dependent covariates for renal transplantation. *Nefrologia.* 2016 Mar-Apr;36(2):156-163. doi: 10.1016/j.nefro.2015.10.007. Epub 2015 Dec 8. Impact\_Factor:1,207
- Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; D'Arminio Monforte A; Kirk O; Ryom L; **Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study**. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with abnormal baseline estimated glomerular filtration rate: a prospective international cohort study. *Lancet HIV.* 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Impact\_Factor:8,364
- Paño B; Macias N; Salvador R; **Torres F**; Bunesch L; Sebastia C; Nicolau C. Usefulness of MDCT to Differentiate Between Renal Cell Carcinoma and Oncocytoma: Development of a Predictive Model. *AJR. AJR Am J Roentgenol.* 2016 Apr;206(4):764-74. doi: 10.2214/AJR.15.14815. Epub 2016 Feb 25. Impact\_Factor:2,66
- Peris F; Donoghue S; **Torres F**; Mian A; Wöber C. Towards improved migraine management: Determining potential trigger factors in individual patients. *Cephalalgia.* 2016 May 14. pii: 0333102416649761. [Epub ahead of print]. Impact\_Factor:6,052
- Peters SA; Bots ML; Canaud B; Davenport A; Grooteman MP; Kircelli F; Locatelli F; Maduell F; Morena M; Nube MJ; Ok E; **Torres F**; Woodward M; Blankestijn PJ. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. *Nephrol Dial Transplant.* 2016 Jun;31(6):978-84. doi: 10.1093/ndt/gfv349. Epub 2015 Oct 22. Impact\_Factor:4,085
- Reig M; **Torres F**; Mariño Z; Fornis X; Bruix J. Reply to Camma et al and Torres et al. *J Hepatol.* 2016 May 30. pii: S0168-8278(16)30250-1. doi: 10.1016/j.jhep.2016.05.036. [Epub ahead of print]. Impact\_Factor:10,59
- Ryom L, Lundgren JD, Ross M, Kirk O, Law M, Morlat P, Smit C, Fontas E, Fux CA, Hatleberg CI, de Wit S, Sabin CA, Mocroft A; **D:A:D Study Group**. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. *J Infect Dis.* 2016 Oct 15;214(8):1212-20. doi: 10.1093/infdis/jiw342. Epub 2016 Aug 2. Impact\_Factor:6,34
- Ryom L; Lundgren JD; De Wit S; Kovari H; Reiss P; Law M; El-Sadr W; D'Arminio Monforte A; Mocroft A; Smith C; Fontas E; Dabis F; Phillips A; Sabin C; **D:A:D Study Group**. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. *AIDS.* 2016 Jul 17;30(11):1731-43. doi: 10.1097/QAD.0000000000001018. Impact\_Factor:4,407
- Sabate A; Gutierrez R; Beltran J; Mellado P; Blasi A; Acosta F; Costa M; Reyes R; **Torres F**. Impact of pre-emptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double-blind, placebo-controlled trial. *Am J Transplant.* 2016 Aug;16(8):2421-9. doi: 10.1111/ajt.13752. Epub 2016 Mar 17. Impact\_Factor:5,669
- Sabin CA; Reiss P; Ryom L; Phillips AN; Weber R; Law M; Fontas E; Mocroft A; De Wit S; Smith C; Dabis F; D'Arminio Monforte A; El-Sadr W; Lundgren JD; **D:A:D Study Group**. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. *BMC Med.* 2016 Mar 31;14(1):61. doi: 10.1186/s12916-016-0588-4. Impact\_Factor:8,005
- Troya MI; Bonet J; Salinas I; **Torres F**; Bonal J; Sanmartí A; Romero R. Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes. *Med Clin (Barc).* 2016 Jan 15;146(2):55-60. doi: 10.1016/j.medcli.2015.05.016. Epub 2015 Sep 3. Impact\_Factor:1,267
- Vidal M; Vidal-Sicart S; **Torres F**; Ruiz DM; Paredes P; Pons F. Correlation between theoretical anatomical patterns of lymphatic drainage and lymphoscintigraphy findings during sentinel node detection in head and neck melanomas. *Eur J Nucl Med Mol Imaging.* 2016 Apr;43(4):626-34. doi: 10.1007/s00259-015-3256-6. Epub 2015 Nov 19. Impact\_Factor:5,537
- 2015**
- Amaro S; Llull L; Renu A; Laredo C; Perez B; Vila E; **Torres F**; Planas AM; Chamorro A. Uric acid improves glucose-driven oxidative stress in human ischemic stroke. *Ann Neurol.* 2015 Jan 27. doi: 10.1002/ana.24378. Impact\_Factor:9,638
- Benito L; Coll-Vinent B; Gomez E; Marti D; Mitjavila J; **Torres F**; Miro O; Siso A; Mont L. EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. *Europace.* 2015 Nov;17(11):1688-93. doi: 10.1093/europace/euv146. Epub 2015 Jun 11. Impact\_Factor:4,021
- Bruyand M; Ryom L; Shepherd L; Fatkenheuer G; Grulich A; Reiss P; De Wit S; D'Arminio Monforte A; Furrer H; Pradier C; Lundgren J; Sabin C; **D:A:D study group**. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D:A:D study. *J Acquir Immune Defic Syndr.* 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523. Impact\_Factor:3,806
- Cabrera-García L; Cruz-Melguizo S; Ruiz-Antoran B; **Torres F**; Velasco A; Martínez-Payo C; Avendano-Sola C. Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial. *Trials.* 2015 Sep 25;16(1):427. doi: 10.1186/s13063-015-0964-y. Impact\_Factor:1,859
- Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; De la Rosa G; Agüero F; Perez I; Gonzalez-Garcia J; Esteban-Mur JI; Miro JM; **FIPSE LT-HIV Investigators**. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. *J Hepatol.* 2015 Jan;62(1):92-100. doi: 10.1016/j.jhep.2014.07.034. Epub 2014 Aug 13. Impact\_Factor:10,59
- Cerini F; Martinez Gonzalez J; **Torres F**; Puente A; Casas M; Vinaixa C; Berenguer M; Ardevol A; Augustin S; Llop E; Senosiain M; Villanueva C; De la Pena J; Baneres R; Genesca J; Sopena J; Albillos A; Bosch J; Hernandez-Gea V; Garcia-Pagan JC. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. *Hepatology.* 2015 Aug;62(2):575-83. doi: 10.1002/hep.27783. Epub 2015 Apr 27. Impact\_Factor:11,711
- Domingo P; Lamarca MK; Gallego-Escuredo MJ; **Torres F**; Domingo JC; Villarroya J; Gutierrez M del Mar; Mateo MG; Vidal F; Villarroya F; M Giralt. Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients. *J Antimicrob Chemother.* 2015;70(6):1825-32. doi: 10.1093/jac/dkv027. Epub 2015 Feb 19. Impact\_Factor:4,919
- Gariup M; Gonzalez A; Lazaro L; **Torres F**; Serra-Pages C; Morer A. IL-8 and the innate immunity as biomarkers in acute child and adolescent psychopathology. *Psychoneuroendocrinology.* 2015 Dec;62:233-42. doi: 10.1016/j.psyneuen.2015.08.017. Epub 2015 Aug 21. Impact\_Factor:4,704
- Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhäus J; Fux CA; Moranne O; Morlat P; Johnson MA; Ryom L; **D:A:D study group**; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. *PLoS Med.* 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015. Impact\_Factor:13,585

Pontes C; Gratacos J; **Torres F**; Avendano C; Sanz J; Vallano A; Juanola X; De Miguel E; Sanmarti R; Calvo G. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. *Trials*. 2015 Aug 20;16(1):370. doi: 10.1186/s13063-015-0828-5. Impact\_Factor:1,859

Silva-Junior G; Baiges A; Turon F; **Torres F**; Hernandez-Gea V; Bosch J; Garcia-Pagan JC. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. *Hepatology* (Baltimore, Md.). *Hepatology*. 2015 Nov;62(5):1584-92. doi: 10.1002/hep.28031. Epub 2015 Sep 30. Impact\_Factor:11,711

Soto GA; Ruiz-Antoran B; Laporta R; Sancho A; Lazaro MT; Herrera CP; Salcedo I; Cos MA; **Torres F**; Usetti P; Avendano-Sola C. Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice- to once-daily tacrolimus oral administration. *Eur J Clin Pharmacol*. 2015 Jun;71(6):715-22. doi: 10.1007/s00228-015-1859-2. Epub 2015 May 9. PMID:25953736. Impact\_Factor:2,71

Trabal J; Forga M; Leyes P; **Torres F**; Rubio J; Prieto E; Farran-Codina A. Effects of free leucine supplementation and resistance training on muscle strength and functional status in older adults: a randomized controlled trial. *Clinical Interventions in Aging* 2015;10 713–723. Impact\_Factor:2,133

## 2014

Busquets C, Ojeda A, **Torres F**, Faulí A, Moreno LA, Bogdanovich A, Giménez-Milà M, Hernández-Cera C, Fàbregas N, Videla S. Desarrollo y validación de un algoritmo para identificar recidivas de cáncer a partir de bases de datos hospitalarias. *Rev Calidad Asistencial* 2014;29(4):229-236doi: 10.1016/j.cali.2014.05.003.

Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Martí-Fàbregas J, Gállego J, Krupinski J, Gomis M, Cánovas D, Carné X, Deulofeu R, Román LS, Oleaga L, **Torres F**, Planas AM; URICO-ICTUS Investigators. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. *Lancet Neurol*. 2014 May;13(5):453-60. doi: 10.1016/S1474-4422(14)70054-7. Epub 2014 Apr 2. Impact\_Factor: 21,896

Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, **Torres F**, Mateo GM, Villarroya J, de Los Santos I, Domingo JC, Villarroya F, Rio LD, Estrada V, Giral M. Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study. *PLoS One*. 2014 Feb 26;9(2):e89088. doi: 10.1371/journal.pone.0089088. eCollection 2014. Impact\_Factor:3,234

Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, **Torres F**, Mateo MG, Villarroya J, Lamarca K, Domingo JC, Vidal F, Villarroya F, Giral M. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz. *J Acquir Immune Defic Syndr*. 2014 Aug 15;66(5):457-65. doi: 10.1097/QAI.0000000000000205. Impact\_Factor:4,39

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; **D:A:D study Group**. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. *BMC Nephrol*. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51. Impact\_Factor:1,69

Muñoz X, Sánchez-Ortiz M, **Torres F**, Villar A, Morell F, Cruz MJ. Diagnostic yield of specific inhalation challenge in hypersensitivity pneumonitis. *Eur Respir J*. 2014 Aug 19. pii: erj00607-2014. Impact\_Factor:1,69

Pallero M, Puy C, Güell R, Pontes C, Martí S, **Torres F**, Antón A, Muñoz X. Ambulatory adaptation to noninvasive ventilation in restrictive pulmonary disease: A randomized trial with cost assessment. *Respir Med*. 2014 Jul;108(7):1014-22. doi: 10.1016/j.rmed.2014.04.016. Epub 2014 May 2. Impact\_Factor:3,086

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin C, El-Sadr W, d'Arminio Monforte A, Phillips A, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren J, Law M; **D:A:D study group**. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. *HIV Med*. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19. Impact\_Factor:3,988

Pontes C, Vives R, **Torres F**, Panés J. Safety and Activity of Dersalazine Sodium in Patients with Mild-to-moderate Active Colitis: Double-blind Randomized Proof of Concept Study. *Inflamm Bowel Dis*. 2014 Nov;20(11):2004-12. doi: 10.1097/MIB.0000000000000166. Impact\_Factor:4,464

Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió I, Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, **Torres F**, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. *Mult Scler*. 2014 May;20(6):717-25. doi: 10.1177/1352458513508835. Epub 2013 Oct 21. Impact\_Factor:4,822

Reig M, **Torres F**, Rodríguez-Lope C, Forner A, Llarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. *J Hepatol*. 2014 Apr 2. pii: S0168-8278(14)00211-6. doi: 10.1016/j.jhep.2014.03.030. Impact\_Factor:11,336

Salazar F, Doñate M, Boget T, Bogdanovich A, Basora M, **Torres F**, Gracia I, Fàbregas N. Relationship between intraoperative regional cerebral oxygen saturation trends and cognitive decline after total knee replacement: a post-hoc analysis. *BMC Anesthesiol*. 2014 Jul 21;14:58. doi: 10.1186/1471-2253-14-58. eCollection 2014. Impact\_Factor:1,375

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Møller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; **D:A:D Study Group**. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet*. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8. Impact\_Factor:45,217

## 2013

Blanco I, Santos S, Gea J, Güell R, **Torres F**, Gimeno-Santos E, Rodríguez DA, Vilaró J, Gómez B, Roca J, Barberà JA. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. *Eur Respir J*. 2013 Oct;42(4):982-92. doi: 10.1183/09031936.00176312. Epub 2013 Feb 21. Impact\_factor: 7,13

Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, Lopez-Callada VR, Salmon D, Sanchez FG, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; **Global H1N1 GBS Consortium**. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. *Vaccine*. 2013 Sep 13;31(40):4448-58. doi: 10.1016/j.vaccine.2013.06.032. Epub 2013 Jun 14. Impact\_factor: 3,44

Domingo P, Cabeza Mdel C, **Torres F**, Salazar J, Gutierrez Mdel M, Mateo MG, Martínez E, Domingo JC, Fernandez I, Villarroya F, Ribera E, Vidal F, Baiget M. Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy. *PLoS One*. 2013;8(2):e57347. doi: 10.1371/journal.pone.0057347. Epub 2013 Feb 28. Impact\_Factor: 3,53

Domingo P, Mateo MG, Pruvost A, **Torres F**, Salazar J, Gutierrez MD; Ma Carmen Cabeza, Domingo JC, Fernandez I, Villarroya F, Vidal F, Baiget M, de la Calle-Martín O. Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B\*40 : 01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. *PLoS One*. 2013 Jun 26;8(6):e67035. Impact\_Factor:3,53

Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, **Torres F**, Campistol JM, Martínez-Castelao A; ESHOL Study Group. High-

- efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *J Am Soc Nephrol*. 2013 Feb;24(3):487-97. doi: 10.1681/ASN.2012080875. Epub 2013 Feb 14. Impact\_Factor: 9,47
- Malouf J, Digregorio S, Rio LD, **Torres F**, Marin AM, Farrerons J, Herrera S, Domingo P. Fat Tissue Measurements by Dual-Energy X-Ray Absorptiometry: Cross-Calibration of 3 Different Fan-Beam Instruments. *J Clin Densitom*. 2013 Apr-Jun;16(2):212-22. doi: 10.1016/j.jocd.2012.04.003. Epub 2012 Jun 13. Impact\_Factor: 1,6
- Moizé V, Andreu A, Flores L, **Torres F**, Ibarzabal A, Delgado S, Lacy A, Rodriguez L, Vidal J. Long-Term Dietary Intake and Nutritional Deficiencies following Sleeve Gastrectomy or Roux-En-Y Gastric Bypass in a Mediterranean Population. *J Acad Nutr Diet*. 2013 Mar;113(3):400-10. doi: 10.1016/j.jand.2012.11.013. Impact\_Factor: 2,44
- Palomar M, Alvarez-Lerma F, Riera A, Díaz MT, **Torres F**, Agra Y, Larizgoitia I, Goeschel CA, Pronovost PJ. Impact of a National Multimodal Intervention to Prevent Catheter-Related Bloodstream Infection in the ICU: The Spanish Experience. *Crit Care Med*. 2013 Oct;41(10):2364-72. doi: 10.1097/CCM.0b013e3182923622. Impact\_factor:6,15
- Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió I Torrenta L, Brieua L, Cano A, Carmona O, Saiz A, **Torres F**, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. *Mult Scler*. 2014 May;20(6):717-25. doi: 10.1177/1352458513508835. Epub 2013 Oct 21. Impact\_factor:4,86
- Reig M, Rimola J, **Torres F**, Darnell A, Lope CR, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. *Hepatology*. 2013 Dec;58(6):2023-31. doi: 10.1002/hep.26586. Epub 2013 Oct 29. Impact\_factor: 11,19
- Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; on behalf of the **D:A:D Study Group**. Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Study. *J Infect Dis*. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4. Impact\_Factor: 5,78
- Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; **D:A:D Study Group**. Associations between immune depression and cardiovascular events in HIV infection. *AIDS*. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3.]. Impact\_Factor: 6,56
- Torres F**, Pontes C. [Missing data: Warrant for search and capture.] *Med Clin (Barc)*. 2013 Oct 5;141(7):297-9. doi: 10.1016/j.medcli.2013.04.001. Epub 2013 May 22. Impact\_factor: 1,25
- Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, Wit SD, Phillips A, Lundgren JD, Sabin CA; **D:A:D Study Group**. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. *BMC Infect Dis*. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471. Impact\_factor: 2,56
- 2012**
- Cabrera-López C, Martí T, Catalá V, **Torres F**, Mateu S, Ballarín J, Torra R. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. *Orphanet J Rare Dis*. 2012 Nov 11;7:87. doi: 10.1186/1750-1172-7-87. Impact\_Factor: 5,074
- Domingo P, Guardiola JM, Salazar J, **Torres F**, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca J, Fontanet A, Martín J, Muñoz J, Vidal F, Baiget M. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. *Antimicrob Agents Chemother*. 2012 Jun;56(6):2987-93. Impact\_Factor: 4,8
- Llupia A, Vilella A, Costas L, Díez C, **Torres F**, Yagüe J, Massó M, Muñoz A, Mensa J. Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted?. *Vaccine*. 2012;30:2382-2386. Impact\_Factor: 3,62
- Margalef P, Fernández-Majada V, Villanueva A, Garcia-Carbonell R, Iglesias M, López L, Martínez-Iniesta M, Villà-Freixa J, Mulero MC, Andreu M, **Torres F**, Mayo MW, Bigas A, Espinosa L. A novel truncated form of IKK $\alpha$  is responsible for nuclear IKK activity in colorectal cancer. *Cell Rep*. 2012 Oct 25;2(4):840-54. doi: 10.1016/j.celrep.2012.08.028. Epub 2012 Oct 4. Impact\_Factor:
- Moizé V, Gluck ME, **Torres F**, Andreu A, Vidal J, Allison K. Transcultural adaptation of the Night Eating Questionnaire (NEQ) for its use in the Spanish population. *Eat Behav*. 2012 Aug;13(3):260-3. Epub 2012 Mar 7. Impact\_Factor: 0
- Muñoz X, Sanchez-Vidaurre S, Roca O, **Torres F**, Morell F, Cruz MJ. Bronchial inflammation and hyperresponsiveness in well controlled asthma. *Clin Exp Allergy*. 2012 Sep;42(9):1321-8. Impact\_Factor: 4,08
- Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; **D:A:D Study Group**. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *J Int AIDS Soc*. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426. Impact\_Factor: 3,256
- Solà R, Valls RM, Godàs G, Perez-Busquets G, Ribalta J, Girona J, Heras M, Cabré A, Castro A, Domenech G, **Torres F**, Masana L, Anglés N, Reguant J, Ramírez B, Barriach JM. Cocoa, hazelnuts, sterols and soluble fiber cream reduces lipids and inflammation biomarkers in hypertensive patients: a randomized controlled trial. *PLoS ONE* 7(2): e31103. doi:10.1371/journal.pone.0031103. Impact\_Factor: 4,41
- Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, D'Arminio Monforte A, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD; **D:A:D Study Group**. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. *J Infect Dis*. 2012;205(4):535-9. Impact\_Factor: 6,4.
- 2011**
- Amaro S, Urrea X, Gómez-Choco M, Obach V, Cervera A, Vargas M, **Torres F**, Rios J, Planas AM, Chamorro A. Uric Acid Levels Are Relevant in Patients With Stroke Treated With Thrombolysis. *Stroke*. 2011 Jan;42(1 Suppl):S28-32. Impact\_Factor:5,729
- Amor AJ, Ricart MJ, **Torres F**, de Hollanda AM, Yago G, Ara P, Esmatjes E. Prevalencia y control de los factores de riesgo cardiovascular en pacientes con diabetes mellitus tipo 1 candidatos a trasplante renopancreático entre los años 1999 y 2010. *Av Diabetol*. 2011;27(4):137-142. Impact\_Factor:2,78
- Cabrera López C, Martí T, Catalá V, **Torres F**, Mateu S, Ballarín Castán J, Torra Balcells R. Effects of Rapamycin on Angiomyolipomas in Patients with Tuberous Sclerosis. *Nefrologia*. 2011;31(3):292-298. Impact\_Factor:1,00
- Cánovas M, **Torres F**, Domenech G, Cebrecos J, Pelagio P, Manríquez M, Martínez G, Arcabell M, Cabré F. Bioequivalence evaluation of two dosage forms of olanzapine 10 mg formulations in healthy volunteers. *Arzneimittelforschung* 2011;61(2):75-79. Impact\_Factor:0,722
- Cánovas M, **Torres F**, Domenech G, Cebrecos J, Pelagio P, Martínez G, Polonio F, Cabré F. Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers. *Arzneimittelforschung*. 2011;61(9):489-93. Impact\_Factor:0,722
- Carrera G, Garcia-Albeniz X, Ayuso JR, Aparicio J, Castells A, Codony-Servat J, Feliu J, Fuster D, Gallego R, Pagés M, **Torres F**, Maurel J. Design And Endpoints Of Clinical And Translational Trials In Advanced Colorectal Cancer. A Proposal From Grupo Español Multidisciplinar En Cancer Digestivo (Gemcad). *Rev Recent Clin Trials*. 2011 May;6(2):158-70.
-

- Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.** The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study. *J Infect Dis.* 2011;204(4):521-5. Impact\_Factor:6,41
- Domingo P, Cabeza MC, Pruvost A, **Torres F**, Salazar J, Gutierrez MD, Mateo MG, Fontanet A, Fernandez I, Domingo JC, Villarroya F, Vidal F, Baiget M. Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. *Antimicrob Agents Chemother.* 2011 Apr;55(4):1428-35. doi: 10.1128/AAC.01589-10. Epub 2011 Jan 31. Impact\_Factor:4,841
- Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD; CoDe Working Group; **D:A:D Study Group.** The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. *Epidemiology.* 2011;22(4):516-23. Impact\_Factor:5,566
- Llupia A, Vilella A, Costas L, Díez C, **Torres F**, Yagüe J, Massó M, Muñoz A, Mensa J. Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted? *Vaccine.* 2011 Sep 28. Impact\_Factor:3,766
- Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Foraster A, Soler J, Galceran JM, Martinez-Castelao A; Online Hemodiafiltration Study Group from the Catalan Society of Nephrology. Impact\_Factor:1,654
- Masclans JR, Roca O, Muñoz X, Pallisa E, **Torres F**, Rello J, Morell F. QUALITY OF LIFE, PULMONARY FUNCTION AND TOMOGRAPHIC SCAN ABNORMALITIES AFTER AN ACUTE RESPIRATORY DISTRESS SYNDROME. *Chest.* 2011 Feb 17. Impact\_Factor:5,25
- Moizé V, Deulofeu R, **Torres F**, de Osaba JM, Vidal J. Nutritional Intake and Prevalence of Nutritional Deficiencies Prior to Surgery in a Spanish Morbidly Obese Population. *Obes Surg.* 2011 Sep;21(9):1382-8. doi: 10.1007/s11695-011-0360-y. Impact\_Factor:3,286
- Obach V, Oleaga L, Urrea X, Macho J, Amaro S, Capurro S, Gomez-Choco M, San Román L, Cervera A, Blasco J, Vargas M, **Torres F**, Chamorro A. Multimodal CT-Assisted Thrombolysis in Patients With Acute Stroke: A Cohort Study. *Stroke.* 2011 Feb 17. Impact\_Factor:5,729
- Ohmann C, Kuchinke W, Canham S, Lauritsen J, Salas N, Schade-Brittinger C, Wittenberg M, McPherson G, McCourt J, Gueyffier F, Lorimer A, **Torres F**, Working Group On Data Centres E. Standard requirements for GCP-compliant data management in multinational clinical trials. *Trials.* 2011 Mar 22;12:85. doi: 10.1186/1745-6215-12-85. Impact\_Factor:2,496
- Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M; **D:A:D Study Group.** Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(\*). *HIV Med.* 2011 Aug;12(7):412-21. Impact\_Factor:3,006
- Salazar F, Doñate M, Boget T, Bogdanovich A, Basora M, **Torres F**, Fàbregas N. Intraoperative warming and post-operative cognitive dysfunction after total knee replacement. *Acta Anaesthesiol Scand.* 2011 Feb;55(2):216-22. doi: 10.1111/j.1399-6576.2010.02362.x.PMID: 21226864. Impact\_Factor:2,188
- 2010**
- Carrión JA, **Torres F**, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. *Hepatology.* 2010 Jan;51(1):23-34. Impact\_Factor:10,89
- Cervera A, Planas AM, Justicia C, Urrea X, Jensenius JC, **Torres F**, Lozano F, Chamorro A. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. *Plos One.* 2010;5(2):e8433. Impact\_Factor:4,41
- Crespo A, Muñoz X, **Torres F**, Martí S, Ferrer J, Morell F. Noninvasive home mechanical ventilation in elderly patients. *Gerontology.* 2010;56(2):150-6. Impact\_Factor:2,20
- Cruz N, Sanchez-Moreno J, **Torres F**, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. *Int J Neuropsychopharmacol.* 2010 Feb;13(1):5-14. Impact\_Factor: 4,70
- Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group,** Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J, Collins S, Dabis. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. *Antivir Ther.* 2010;15(8):1077-86. Impact\_Factor:3,77
- Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Worm SW, Friis-Møller N, Sabin CA, Sjørl A, Lundgren JD, Salbøl-Brandt R, Rickenbach M, Pezzotti P, Krum E, Gras L, Balestre E, Sundström A, Delforge M, Fontas E, **Torres F**, P. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS* 2010; 24(10):1537-48. Impact\_Factor:6,35
- Escorsell A, **Torres F**, Bookman I, Mas A, Rios J, Fernandez J, Gines R. Early identification of prognostic factors of death in acute-on-chronic liver failure. *Journal of Hepatology.* 2010;52(Suppl.1):S72-S72. Impact\_Factor: 9,33
- Esteva-Font C, Wang X, Ars E, Guillén-Gómez E, Sans L, González Tabuerna I, **Torres F**, Torra R, Masilamani S, Ballarín JA, Fernández-Llama P. Are Sodium Transporters in Urinary Exosomes Reliable Markers of Tubular Sodium Reabsorption in Hypertensive Patients? *Nephron Physiol.* 2010 Jan 12;114(3):p25-p34. Impact\_Factor:2,53
- Friis-Møller N, Thiébaud R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; **DAD study group.** Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil.* 2010;17(5):491-501. Impact\_Factor:2,63
- Izquierdo I, Borja J, Rovira S, Pelagio P, **Torres F**, Cebrecos J, García-Rafanell J. Comparative bioavailability study of triflusal oral solution vs. Triflusal capsules in healthy subjects. *Arzneimittelforschung* 2010;60(1):36-41. Impact\_Factor:0,69
- Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, Leizorovicz A, Schade-Brittinger C, Wittenberg M, Voko Z, Gaynor S, Cooney M, Doran P, Maggioni A, Lorimer A, **Torres F**, McPherson G, Charwill J, Hellström M, Lejeune S. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. *Trials.* 2010;11:79. Impact\_Factor:2,02
- Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; **SPIRAL Study Group.** Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. *AIDS.* 2010;24(11):1697-707. Impact\_Factor:6,35
- Roca O, Masclans JR, Muñoz X, **Torres F**, Morell F, Rello J. Health related quality of life in ards survivors: importance of the early measurement. *Intensive Care Medicine* 2010;36(Suppl.2):S229-S229. Impact\_Factor: 5,00
- Roca O, Riera J, **Torres F**, Masclans JR. High-flow oxygen therapy in acute respiratory failure. *Respir Care.* 2010 Apr;55(4):408-13. Impact\_Factor:1,53
- Solà R, Bruckert E, Valls RM, Narejos S, Luque X, Castro-Cabezas M, Doménech G, **Torres F**, Heras M, Farrés X, Vaquer JV, Martínez JM, Almaraz MC, Anguera A. Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic patients: A randomised trial. *Atherosclerosis.* 2010;211(2):630-7. Impact\_Factor:4,09
- Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, **Torres F**, Cardona PJ, Costa J. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. *Vaccine.* 2010 Jan 22;28(4):1106-16. Impact\_Factor:3,57

Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; **D:A:D study group**. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. *AIDS*. 2010;28;24(3):427-35. Impact\_Factor:6,35

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J, for the **D:A:D Study Group**. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis*. 2010 Feb 1;201(3):318-30. Impact\_Factor:6,29

#### 2009

Cánovas M, Delgado J, **Torres F**, Riba N, Cebrecos J, Pelagio P, Cabré F. Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. *Int J Clin Pharmacol Ther* 2009;47(2):124-31. Impact\_Factor:1,38

Carne X, **Ríos J**, **Torres F**. Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care. *Methods Find Exp Clin Pharmacol*. 2009 Oct;31(8):533-40. Impact\_Factor:1,14

Cruz N, Sanchez-Moreno J, **Torres F**, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. *Int J Neuropsychopharmacol*. 2009 Jul 29:1-10. Impact\_Factor: 4,87

Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Pradier C, Thiebaut R, Law M, Rickenbach M, Stéphane DW, Lundgren JD, Møller NF, **Data Collection on Adverse Events of Anti-HIV Drugs (The D:A:D study)**. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. *Diabetes Care* 2009;32(3):474-80. Impact\_Factor:6,72

De Gottardi A, Thévenot T, Spahr L, Morard I, Bresson-Hadni S, **Torres F**, Giostra E, Hadengue A. Risk of Complications After Abdominal Paracentesis in Cirrhotic Patients: A Prospective Study. *Clin Gastroenterol Hepatol*. 2009;7(8):906-9. Impact\_Factor:5,64

Domingo P, Suarez-Lozano I, **Torres F**, Pomar V, Ribera E, Galindo MJ, Cosin J, Garcia-Alcalde ML, Vidal F, Lopez-Aldeguer J, Roca B, Gonzalez J, Lozano F, Garrido M; on behalf of the VACH Cohort Study Group. Bacterial Meningitis in HIV-1-Infected Patients in the Era of Highly Active Antiretroviral Therapy. *J Acquir Immune Defic Syndr*. 2009;51(5):582-7. Impact\_Factor:4,21

Fabregas N, Salazar F, Doñate M, **Torres F**, Boget T. Regional Brain O2 Desaturation Is an Independent Risk Factor for Postoperative Cognitive Dysfunction. *J. Neurosurg Anesthesiol* 2009;21(4) October Abstract A1413. Impact\_Factor: 2,41

Fontseré N, Esteve V, Saurina A, Pou M, Barba N, Deulofeu R, Di Gregorio S, Del Rio LM, **Ríos J**, **Torres F**, Maduell F, Campistol JM, Ramírez de Arellano M. The Search for a New Marker of Renal Function in Older Patients with Chronic Kidney Disease Stages 3-4: Usefulness of Cystatin C-Based Equations. *Nephron Clin Pract*. 2009 Apr 24;112(3):c164-c170. Impact\_Factor:1,61

Guevara M, Baccaro ME, Torre A, Gómez-Ansón B, **Ríos J**, **Torres F**, Rami L, Monté-Rubio GC, Martín-Llahí M, Arroyo V, Ginès P. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. *Am J Gastroenterol*. 2009 Jun;104(6):1382-9. Impact\_Factor:6,01

Monzón S, Arrondo E, Bartra J, **Torres F**, Basagaña M, SanMiguel MM, Alonso R, Cisteró-Bahima A. Conjunctivitis and Total IgE in Lacrimal Fluid: Lacrytest Screening. *Journal of Allergy* 2009, Article ID 518903, 6 pages, doi:10.1155/2009/518903. Impact\_Factor: 9,16

Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernández-Majada V, Grilli A, López-Bigas N, Bellora N, Albà MM, **Torres F**, Duñach M, Sanjuan X, Gonzalez S, Gridley T, Capella G, Bigas A, Espinosa L. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. *PNAS* 2009; 106: 6315-6320. Impact\_Factor:9,43

**The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)**. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). *Circulation*. 2009;119(6):805-11. Impact\_Factor:14,82

#### 2008

Atienzar MC, Palanca JM, **Torres F**, Borrás R, Gil S, Esteve I. A randomized comparison of levobupivacaine, bupivacaine and ropivacaine with fentanyl, for labor analgesia. *International Journal of Obstetric Anesthesia* 2008;17:106–111. Impact\_Factor:1,85

Basagaña M, Bartolomé B, Pastor C, Torres F, Alonso R, Vivancos F, Cisteró-Bahima A. Allergy to Human Seminal Fluid: Cross-Reactivity with Dog Dander. *J Allergy Clin Immunol*. 2008 Jan;121(1):233-9. PMID: 18061650. Impact\_Factor:9,17

**Data Collection on Adverse Events of Anti-HIV Drugs Study Group**. Sabin CA, d'Arminio Monforte A, Friis-Møller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. *Clin Infect Dis*. 2008 Apr 1;46(7):1101-10. PMID: 18461712. Impact\_Factor:8,26

De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips A; **Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study**. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. *Diabetes Care* 2008; 31(6):1224-9. PMID: 18268071. Impact\_Factor:7,34

**D:A:D Study Group**. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet*. 2008 Apr 26;371(9622):1417-26. E pub 2008 Apr 2. PMID: 18387667 Domingo P, Suarez-Lozano I, Teira R, Lozano F, Terrón A, Viciana P, González J, Galindo MJ, Guijo P, Vergara A, Cosin J, Ribera E, Roca B, García-Alcalde ML, Sánchez T, **Torres F**, Lacalle JR and Garrido M. Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort. *The Open AIDS Journal*, 2008, 2, 26-38. Impact\_Factor:28,4

Domingo P, Suarez-Lozano I, **Torres F**, Teira R, Lopez Aldeguer J, Vidal F, Muñoz A, Viciana P, Lozano F, Vergara A, Roca B, Garcia A ML, Cosin J, Terron A, Galindo MJ, Geijo, P, Ribera, E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA Study, a non-randomized comparison from the VACH Cohort. *Journal of Antimicrobial Chemotherapy*, (2008) 61, 1348–1358. doi:10.1093/jac/dkn121. Advance Access publication 20 March 2008. PMID: 18356150. Impact\_Factor:4,35

Fontseré N, Bonal J, Salinas I, Ramírez de Arellano M, Ríos J, **Torres F**, Sanmartí A, Romero R. Is the New Mayo Clinic Quadratic Equation Useful for the Estimation of Glomerular Filtration Rate in Type 2 Diabetic Patients? *Diabetes Care* 2008 Diciembre,31,12,2265-67. Impact\_Factor:6,72

Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, Ferro JM, Gomez-Anson B, Manubens JM, Martinez-Lage JM, Muñoz D, Peña-Casanova J, **Torres F** on behalf of the TRIMCI Study Group. A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment. *The TRIMCI Study*. *Alzheimer Dis Assoc Disord*. 2008 Jan-Mar;22(1):21-9. PMID: 18317243. Impact\_Factor:2,88



Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; **Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group**. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. A Monforte, D Abrams, C Pradier, R Weber, P Reiss, F Bonnet, O Kirk, M Law, S De Wit, N Friis-Møller, AN Phillips, CA Sabin, JD Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. AIDS. 2008 Oct 18;22(16):2143-53. PMID: 18832878. Impact\_Factor:5,46

Muñoz X, **Torres F**, Sampol G, Rios J, Martí S, Escrich E. Accuracy and Reliability of Pulse Oximetry at Different PaCO<sub>2</sub> Levels. Eur Respir J. 2008 Oct;32(4):1053-9. doi: 10.1183/09031936.00126507. Epub 2008 May 14. Impact\_Factor:5,53

Salas-Salvadó J, Farrés X, Luque X, Narejos S, Borrell M, Basora J, Anguera A, **Torres F**, Bulló M, Balanza R for the Fiber in Obesity-Study Group\*. Effect of a Mixture of Fibres on Body Weight and Metabolic Variables in Overweight or Obese Patients. British Journal of Nutrition Br J Nutr. 2008 Jun;99(6):1380-7. Epub 2007 Nov 22. PMID: 18031592. Impact\_Factor:3,45

Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008, 22(14):F17-F24. Impact\_Factor:5,46

Trullàs JC, Barril G, Cofan F, Moreno A, Cases A, Fernandez-Lucas M, Martinez-Ara J, Ceballos M, Garcia-de-Diego J, Muñoz ML, Molina J, Martínez-Castelao A, González-García J, Miró JM; and the **Spanish HIV Infection in Dialysis Study Group**. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res Hum Retroviruses. 2008;24(10):1229-1235. Impact\_Factor:2,02

### **Participation in independent investigation projects with competitive financing**

PROJECT TITLE: SCReN. Spanish Clinical Research Network  
FINANCING ENTITY: ISCIII (Spain)  
PRINCIPAL RESEARCHER for the Biostats Program: Ferran Torres Benítez  
DURATION: from 2014-2018

PROJECT TITLE: Advances in Small Trials dEsign for Regulatory Innovation and eXcelence (ASTERIX)  
FINANCING ENTITY FP7-HEALTH-2013-INNOVATION-1  
PRINCIPAL RESEARCHER WP5: Ferran Torres Benítez  
DURATION: from 2013-2017

PROJECT TITLE: European Clinical Research Infrastructures Network and biotherapies facilities in Spain- ECRIN. ECRIN-Preparation Phase Infrastructure  
FINANCING ENTITY: Comissió Europea. 7 Programa Marco  
DURATION: from 2009 to 2011  
PRINCIPAL RESEARCHER: Jaques Demotes/ Spanish Coordinator: Xavier Carné

PROJECT TITLE: European Clinical Research Infrastructures Network and biotherapies facilities in Spain- ECRIN). ECRIN-Transnational Working Groups (TWG, 2006-2008)  
FINANCING ENTITY: Comissió Europea. 6 Programa Marco  
DURATION: from 2006 to 2008  
PRINCIPAL RESEARCHER: Jaques Demotes/ Coord.nacional: Xavier Carné / Data Management: Ferran Torres

PROJECT TITLE: Consolidación proyecto European Clinical Research Infrastructures Network and biotherapies en España  
FINANCING ENTITY: MEC. Dirección general de Política y Tecnología  
DURATION: from 2007 to 2009  
PRINCIPAL RESEARCHER: Xavier Carné.

PROJECT TITLE: Efectividad de Los Inhibidores del Eje Renina-Angiotensina en Pacientes con Diabetes Mellitus Tipo 2 e Hipertensión Arterial en Catalunya. Estudio de Cohortes IERACAT.  
FINANCING ENTITY: FIS EC07/90010  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Rosa Morros Pedrós

PROJECT TITLE: Tratamiento de los Tumores Vasculares de la Infancia y el Desarrollo con Bevacizumab  
FINANCING ENTITY: FIS EC07/90139  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Jaume Mora Graupera

PROJECT TITLE: Uricotictus-fase III. Estudio doble ciego, aleatorizado frente a vehiculo de la eficacia clínica del tratamiento combinado con ácido úrico y RTPA administrados por vía intravenosa en pacientes con ictus isquémico de menos de 3 horas de evolución.  
FINANCING ENTITY: FIS EC07/90276  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Angel Chamorro Sanchez

PROJECT TITLE: Ensayo Clínico para Evaluar la Eficacia y Seguridad de la Rapamicina en los Angiomiolipomas en Pacientes con Esclerosis Tuberosa.  
FINANCING ENTITY: FIS EC07/90025  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Roser Torra Balcells

PROJECT TITLE: Utilidad de la detección precoz de la fibrilación auricular.  
FINANCING ENTITY: FIS PI070278  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Blanca Coll-Vinent Puig.

PROJECT TITLE: Estudio aleatorizado y abierto de la eficacia, seguridad y tolerabilidad de dosis repetidas de bevacizumab intravitreo en pacientes con edema macular uveítico  
FINANCING ENTITY: FIS  
DURATION: FROM 2008 TO 2011  
PRINCIPAL RESEARCHER: Alfredo Adán Civera

PROJECT TITLE: Ensayo de fase 2, brazo único, abierto, con irinotecan en combinación con CIS-Platino en pacientes pediátricos con gliomas de mal pronóstico  
FINANCING ENTITY: PFIS0067 EC08/00211  
DURATION: FROM 2008 TO 2011  
PRINCIPAL RESEARCHER: Ofelia Cruz.

PROJECT TITLE: Eficacia de dos sistemas de ahorro de oxígeno líquido en deambulación  
FINANCING ENTITY: FIS PI07/90074  
DURATION: FROM 2007 TO 2008  
PRINCIPAL RESEARCHER: Sergi Martí Beltran.

PROJECT TITLE: Estudio clínico y epidemiológico de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) en el paciente de edad avanzada en la era del tratamiento antiretroviral de gran actividad (TARGA). Estudio comparativo observacional de casos y controles en base de datos informatizada. Grupo Español de Estudios Observacionales VACH (Grupo VACH)  
FINANCING ENTITY: FIPSE.  
DURATION: FROM 2006 TO 2008.  
PRINCIPAL RESEARCHER: Dra. M<sup>a</sup> Antonia Sambeat/Dr. Pere Domingo.

PROJECT TITLE: Estrategias terapéuticas en Trastorno Depresivo Mayor resistente a tratamiento con Inhibidores Selectivos de la Recaptación de la Serotonina. Ensayo clínico pragmático, paralelo, aleatorizado con evaluación enmascarada  
FINANCING ENTITY: FIS (Cód. EudraCT: 2007-002130-11)  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Dr Víctor Pérez Sola.

PROJECT TITLE: Training project to the Polish Regulatory Medical Agency.  
FINANCING ENTITY: FIIAPP (Fundación Internacional y para Ibero-América de Administración y Políticas Públicas).  
DURATION FROM 2004 TO 2004.  
PRINCIPAL RESEARCHER: Ferran Torres.

PROJECT TITLE: Data Collection on Adverse Events on anti-HIV Drugs (D:A:D Study).  
FINANCING ENTITY: FIPSE.  
DURATION FROM 2000 TO 2000.  
PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo.

PROJECT TITLE: Data Collection on Adverse Events on anti-HIV Drugs (D:A:D Study).  
FINANCING ENTITY: Committee for Proprietary Medicinal Products (CPMP).  
DURANTION FROM 2000 TO 2000.  
PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo.

PROJECT TITLE: Estudio multicéntrico internacional para evaluar el riesgo cardiovascular asociado a la utilización de antiretrovirales en pacientes VIH positivos.  
FINANCING ENTITY: FIPSE.  
DURATION FROM 2000 TO 2000.  
PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo.

PROJECT TITLE: Estudio para evaluar el perfil de seguridad de los fármacos antiretrovirales en pacientes VIH positivos controlados en régimen ambulatorio.  
FINANCING ENTITY: FIS (PI 99/0887)  
DURATION FROM 1999 TO 2000.  
PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo